Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

Completed · Phase 1/Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.

Key facts

Study ID

NCT00103831

Run by

Bristol-Myers Squibb

Last updated by the study team

2010-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced or metastatic pretreated NSCLC
• Measurable disease
• Adequate hematologic, hepatic and renal functions.
• ECOG Performance Status 0-2

You may not qualify if…

• Inability to swallow capsules
• Recent significant cardiovascular disease
• Women who are pregnant or breastfeeding

Where it is running

• Local Institution — Denver, Colorado, United States
• Local Institution — Rochester, Minnesota, United States
• Local Institution — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.